Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Champlin

Showing results (481-490 of 768) with videos related to

Pageof 77
Sort By:
Blood|August 25, 2017
Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantationStefan O Ciurea, Jolie R Schafer, Roland Bassett, et al.
Bone Marrow Transplantation|October 20, 2018
Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantationMithun Vinod Shah, Rima M Saliba, Gabriela Rondon, et al.
Cancer|September 30, 2016
Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myelomaIdrees Mian, Denái R Milton, Nina Shah, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 2, 2008
Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trialMuzaffar H Qazilbash, Rima M Saliba, Yago Nieto, et al.
Haematologica|August 26, 2021
Refined HLA-DPB1 mismatch with molecular algorithms predicts outcomes in hematopoietic stem cell transplantationJun Zou, Piyanuch Kongtim, Betül Oran, et al.
Frontiers in Immunology|October 31, 2022
Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCyJun Zou, Piyanuch Kongtim, Samer A Srour, et al.
Bone Marrow Transplantation|September 19, 2023
Hematopoietic cell transplantation can be safely performed after COVID-19Alejandro Marinos, Jeremy Ramdial, Fareed Khawaja, et al.
Current Research in Translational Medicine|January 27, 2019
HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplantArmin Ghobadi, Denái R Milton, Lohith Gowda, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 27, 2007
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalanBetul Oran, Sergio Giralt, Rima Saliba, et al.
Bone Marrow Transplantation|January 31, 2007
Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myelomaM H Qazilbash, R M Saliba, C Hosing, et al.
Pageof 77

Showing results (481-490 of 768) with videos related to

Sort By:
Pageof 77
Blood|August 25, 2017
Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantationStefan O Ciurea, Jolie R Schafer, Roland Bassett, et al.
Bone Marrow Transplantation|October 20, 2018
Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantationMithun Vinod Shah, Rima M Saliba, Gabriela Rondon, et al.
Cancer|September 30, 2016
Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myelomaIdrees Mian, Denái R Milton, Nina Shah, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 2, 2008
Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trialMuzaffar H Qazilbash, Rima M Saliba, Yago Nieto, et al.
Haematologica|August 26, 2021
Refined HLA-DPB1 mismatch with molecular algorithms predicts outcomes in hematopoietic stem cell transplantationJun Zou, Piyanuch Kongtim, Betül Oran, et al.
Frontiers in Immunology|October 31, 2022
Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCyJun Zou, Piyanuch Kongtim, Samer A Srour, et al.
Bone Marrow Transplantation|September 19, 2023
Hematopoietic cell transplantation can be safely performed after COVID-19Alejandro Marinos, Jeremy Ramdial, Fareed Khawaja, et al.
Current Research in Translational Medicine|January 27, 2019
HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplantArmin Ghobadi, Denái R Milton, Lohith Gowda, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 27, 2007
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalanBetul Oran, Sergio Giralt, Rima Saliba, et al.
Bone Marrow Transplantation|January 31, 2007
Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myelomaM H Qazilbash, R M Saliba, C Hosing, et al.
Pageof 77